A full list of Publications can be found here

Recent Publications

Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease

Wang W, Peng D, Baptista RP, Li Y, Kissinger JC, Tarleton RL (2021) Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease. PLoS Pathog 17(1): e1009254. https://doi.org/10.1371/journal.ppat.1009254

 

A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses

Huifeng Shen, David Forgacs, Digantkumar Chapla, Kelley W. Moremen, Lance Wells, Sarah A. Hamer, Stephen M. Tompkins, Ted M. Ross, Nadine Rouphael, Srilatha Edupuganti, Matthew H. Collins, Rick L. Tarleton

medRxiv 27 Jan 2021 doi: https://doi.org/10.1101/2021.01.20.21249279

 

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease

Bustamante JM, Sanchez-Valdez F, Padilla A, White BE, Wang W, Tarleton RL.

Science Translational Medicine  28 Oct 2020: Vol. 12, Issue 567, eabb7656 DOI: 10.1126/scitranslmed.abb7656

 

Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion.

Pack AD, Tarleton RL.

J Immunol. 2020 Aug 1;205(3):573-578. doi: 10.4049/jimmunol.2000218. Epub 2020 Jun 26. PubMed PMID: 32591392; PubMed Central PMCID: PMC7369248.

 

Chagas Disease Drug Discovery: Multiparametric Lead Optimization Against Trypanosoma cruzi in Acylaminobenzothiazole Series.

Fleau C, Padilla A, Miguel-Siles J, Quesada-Campos MT, Saiz-Nicolas I, Cotillo I, Cantizani Perez J, Tarleton RL, Marco M, Courtemanche G.

J Med Chem. 2019 Nov 27;62(22):10362-10375. doi: 10.1021/acs.jmedchem.9b01429. Epub 2019 Nov 18.

 

Protozoan persister-like cells and drug treatment failure.

Barrett MP, Kyle DE, Sibley LD, Radke JB, Tarleton RL.

Nat Rev Microbiol. 2019 Oct;17(10):607-620. doi: 10.1038/s41579-019-0238-x. Epub 2019 Aug 23. Review.

 

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Rao SPS, Barrett MP, Dranoff G, Faraday CJ, Gimpelewicz CR, Hailu A, Jones CL, Kelly JM, Lazdins-Helds JK, Mäser P, Mengel J, Mottram JC, Mowbray CE, Sacks DL, Scott P, Späth GF, Tarleton RL, Spector JM, Diagana TT.

ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.

 

Highly Competent, Non-Exhausted CD8+ T Cells Continue to Tightly Control Pathogen Load Throughout Chronic Trypanosoma Cruzi Infection.

Pack AD, Collins MH, Rosenberg CS, Tarleton RL.

PLoS Pathog. 2018 Nov 12;14(11):e1007410. doi: 10.1371/journal.ppat.1007410. eCollection 2018 Nov.

 

Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes.

Albareda MC, Natale MA, De Rissio AM, Fernandez M, Serjan A, Alvarez MG, Cooley G, Shen H, Viotti R, Bua J, Castro Eiro MD, Nuñez M, Fichera LE, Lococo B, Scollo K, Tarleton RL, Laucella SA.

Front Immunol. 2018 Sep 13;9:1958. doi: 10.3389/fimmu.2018.01958. eCollection 2018.

 

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure.

Sánchez-Valdéz FJ, Padilla A, Wang W, Orr D, Tarleton RL.

Elife. 2018 Mar 26;7. pii: e34039. doi: 10.7554/eLife.34039.

 

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.

Sanchez Alberti A, Bivona AE, Cerny N, Schulze K, Weißmann S, Ebensen T, Morales C, Padilla AM, Cazorla SI, Tarleton RL, Guzmán CA, Malchiodi EL.

NPJ Vaccines. 2017 Apr 10;2:9. doi: 10.1038/s41541-017-0010-z. eCollection 2017.

 

Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.

Soares Medeiros LC, South L, Peng D, Bustamante JM, Wang W, Bunkofske M, Perumal N, Sanchez-Valdez F, Tarleton RL.

mBio. 2017 Nov 7;8(6). pii: e01788-17. doi: 10.1128/mBio.01788-17.